KARYOPHARM THERAP.DL-0001KARYOPHARM THERAP.DL-0001KARYOPHARM THERAP.DL-0001

KARYOPHARM THERAP.DL-0001

No trades
See on Supercharts
Next report date
Report period
EPS estimate
Revenue estimate
Market capitalization
‪104.92 M‬EUR
−1.1820EUR
‪−129.65 M‬EUR
‪132.31 M‬EUR
‪110.07 M‬
Beta (1Y)
1.48

About Karyopharm Therapeutics Inc.

CEO
Richard A. Paulson
Headquarters
Newton
Employees (FY)
325
Founded
2008
FIGI
BBG00645T1K4
Karyopharm Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. Its Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). Karyopharm’s compound, XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. In addition to single-agent and combination activity against a variety of human cancers, SINE compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses, and wound-healing. Karyopharm has several investigational programs in clinical or preclinical development. The company was founded by Joseph Araujo, Ronald A. DePinho, Pamela A, Silver, Giulio Draetta, Michael G. Kauffman, and Sharon Shacham on December 22, 2008 and is headquartered in Newton, MA.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.

Frequently Asked Questions

Depending on the exchange, the stock ticker may vary. For instance, on FWB exchange KARYOPHARM THERAP.DL-0001 stocks are traded under the ticker 25K.
We've gathered analysts' opinions on KARYOPHARM THERAP.DL-0001 future price: according to them, 25K price has a max estimate of 7.47 EUR and a min estimate of 1.87 EUR. Watch 25K chart and read a more detailed KARYOPHARM THERAP.DL-0001 stock forecast: see what analysts think of KARYOPHARM THERAP.DL-0001 and suggest that you do with its stocks.
25K reached its all-time high on Dec 8, 2014 with the price of 39.1520 EUR, and its all-time low was 0.6040 EUR and was reached on Nov 30, 2023. View more price dynamics on 25K chart.
See other stocks reaching their highest and lowest prices.
Yes, you can track KARYOPHARM THERAP.DL-0001 financials in yearly and quarterly reports right on TradingView.
KARYOPHARM THERAP.DL-0001 is going to release the next earnings report on Aug 1, 2024. Keep track of upcoming events with our Earnings Calendar.
25K earnings for the last quarter are −0.30 EUR per share, whereas the estimation was −0.31 EUR resulting in a 4.15% surprise. The estimated earnings for the next quarter are −0.29 EUR per share. See more details about KARYOPHARM THERAP.DL-0001 earnings.
KARYOPHARM THERAP.DL-0001 revenue for the last quarter amounts to ‪30.70 M‬ EUR, despite the estimated figure of ‪31.96 M‬ EUR. In the next quarter, revenue is expected to reach ‪33.81 M‬ EUR.
25K net income for the last quarter is ‪−34.63 M‬ EUR, while the quarter before that showed ‪−37.90 M‬ EUR of net income which accounts for 8.65% change. Track more KARYOPHARM THERAP.DL-0001 financial stats to get the full picture.
No, 25K doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Jul 20, 2024, the company has 325.00 employees. See our rating of the largest employees — is KARYOPHARM THERAP.DL-0001 on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. KARYOPHARM THERAP.DL-0001 EBITDA is ‪−122.41 M‬ EUR, and current EBITDA margin is −88.34%. See more stats in KARYOPHARM THERAP.DL-0001 financial statements.
Like other stocks, 25K shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade KARYOPHARM THERAP.DL-0001 stock right from TradingView charts — choose your broker and connect to your account.